Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market-(Pipeline Forecast & Market Forecast in G8 Countries) (2011-2020)

世界の急性リンパ性白血病/急性リンパ芽球性白血病治療市場

◆タイトル:Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market-(Pipeline Forecast & Market Forecast in G8 Countries) (2011-2020)
◆商品コード:MAM40116001
◆調査・発行会社:MarketsandMarkets
◆発行日:2013年12月
◆ページ数:157
◆レポート形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:世界主要地域
◆販売価格オプション(消費税別)
Single userUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界の急性リンパ性白血病/急性リンパ芽球性白血病治療市場"について調査・分析し、イントロダクション、エグゼクティブサマリー、市場概観、市場の成長要因、阻害要因、市場の機会と課題、市場の動態、地域別分析、市場規模及び予測、主要企業(ベンダー)分析等の情報をお届けいたします。

The acute lymphocytic/lymphoblastic leukemia therapeutics market has growth potential as the incidence rate of the disease is increasing all over the globe. The incidence of acute lymphocytic/lymphoblastic leukemia is higher in children from 0 to 14 years than in those aged 15 years and above. However, acute lymphocytic/lymphoblastic leukemia may also occur in adults. The acute lymphocytic/lymphoblastic leukemia market is segmented into two types—childhood acute lymphocytic/lymphoblastic leukemia and adult acute lymphocytic/lymphoblastic leukemia.

The acute lymphocytic/lymphoblastic leukemia therapeutics market primarily covers regimens and drugs (patented, off-patent, and pipeline). The growing acute lymphocytic/lymphoblastic leukemia population is an impetus for the growth of the market. This market is expected to grow at a CAGR of 4.0% from 2015 to 2020. In 2012, the overall ALL therapeutics market was dominated by Linker regimen, Hyper-CVAD regimen, and Nucleoside metabolic inhibitors treatments. However, by 2020, the overall share of these drugs and regimens will be largely impacted by the launch of Graspa (ERYtechPharma), an innovative form of L-Asparaginase, followed by Marqibo (Talon Therapeutics) and Inotuzumab Ozogamicin (Pfizer, Inc.).

In contrast to the growth of the market, the cost of the therapies is majorly restraining the acute lymphocytic/lymphoblastic leukemia therapeutics market. In addition, patent expirations of some of the existing drugs in the market are also expected to limit the market growth during 2013 to 2020.

Market players are implementing various growth strategies in the market to gain a competitive edge. New product launches, product pipelines, agreements and collaborations, clinical trials, and acquisitions were some of the major strategies adopted by the players from January 2008 to November 2013.

Scope of the report:

This research report categorizes the acute lymphocytic/lymphoblastic leukemia market in G8 countries into the following segments:

Acute Lymphocytic/Lymphoblastic Leukemia Market, by Drug
Existing Regimens/Drugs
Hyper-CVAD Regimen
CALGB 8811 Regimen
Linker Regimen
Nucleoside Metabolic Inhibitors (Clolar and Nelarabine)
Oncaspar
Pipeline Drugs (Phase III)
Graspa
Marqibo
Inotuzumab Ozogamicin
Acute Lymphocytic/Lymphoblastic Leukemia Market, by Geography
North America
U.S.
Canada
Europe
Germany
France
Italy
Spain
U.K.
Japan

【レポートの目次】

1 Introduction (Page No. – 16)
1.1 Objectives of The Study
1.2 Report Description
1.3 Markets Covered
1.4 Stakeholders
1.5 Research Methodology
1.5.1 Market Size Estimation and Data Triangulation
1.5.2 Market Estimation Model
1.5.3 Key Data Points Taken From Secondary Sources
1.5.4 Assumptions Made For This Report

2 Executive Summary (Page No. – 31)

3 Market Overview (Page No. – 36)
3.1 Defining Leukemia
3.2 Acute Lymphocytic Leukemia
3.2.1 Risk Factors
3.2.2 Stages/Risk Groups of Acute Lymphocytic Leukemia
3.2.2.1 Childhood All
3.2.2.1.1 Standard (LOW) Risk
3.2.2.1.2 High Risk
3.2.2.1.3 Recurrent
3.2.2.2 Adult All
3.2.2.2.1 Untreated Adult All
3.2.2.2.2 Adult All in Remission
3.2.2.2.3 Recurrent Adult All
3.2.3 Diagnosis
3.2.3.1 Biopsy and Bone Marrow Aspiration
3.2.3.2 Complete Blood Count (CBC) and Differential
3.2.3.3 Presence of Philadelphia Chromosome
3.2.3.4 Spinal Tap (Lumbar Puncture) and Cerebrospinal Fluid (CSF) Analysis
3.2.3.5 Immunophenotyping Or Phenotyping By Flow Cytometry
3.2.3.6 Polymerase Chain Reaction (PCR)
3.2.4 Leukemia Prevalence
3.2.5 Incidence & Mortality
3.3 Market Structure
3.3.1 Key Therapies
3.3.1.1 Chemotherapy
3.3.1.2 Stem Cell/Bone Marrow Transplant
3.3.1.3 Radiation Therapy

4 Acute Lymphocytic Leukemia Therapeutics Market Dynamics (Page No. – 49)
4.1 Market Overview
4.2 Market Dynamics
4.2.1 Market Drivers
4.2.1.1 Innovative Therapies to Drive The Market For Acute Lymphocytic Leukemia
4.2.1.2 Oncology Is The Largest Therapeutic Market With High Unmet Needs
4.2.2 Market Restraints
4.2.2.1 Costs Associated With The Treatment
4.2.2.2 Adverse Events of Treatment
4.2.2.3 Low Production Capability of Drugs
4.2.2.4 Genericiazation of The Major Drugs
4.2.3 Market Opportunities
4.2.3.1 Limited Players in The Market
4.2.3.2 Leukemia’s Underserved Patient Populations offer Potential For Market Growth
4.3 Burning Issues
4.4 Winning Imperatives
4.4.1 Market Expansion Through Multiple Therapeutic Approaches

5 Leukemia Product Market (Page No. – 59)
5.1 Market Overview
5.1.1 Hyper-Cvad Regimen
5.1.2 Calgb 8811 Regimen
5.1.3 Linker Regimen
5.1.4 Nucleoside Metabolic Inhibitors (Clolar + Arranon)
5.1.5 Oncaspar

6 Acute Lymphocytic Leukemia Pipeline Molecules (Phase Iii)(Page No. – 73)
6.1 Introduction
6.1.1 Graspa
6.1.2 Marqibo
6.1.3 Inotuzumab Ozogamicin

7 Geographic Analysis (Page No. – 81)
7.1 Introduction
7.2 U.S.
7.3 Canada
7.4 U.K.
7.5 Germany
7.6 France
7.7 Italy
7.8 Spain
7.9 Japan

8 Company Profiles (Overview, Financials, Products Portfolio, Growth Strategy, and Developments)* (Page No. – 126)
8.1 Erytech Pharma
8.2 Genzyme Corporation
8.3 Talon Therapeutics, Inc. (Spectrum Pharmaceuticals, Inc.)
8.4 Sigma-Tau Pharmaceuticals, Inc.
8.5 Pfizer Inc
8.6 Glaxosmithkline Plc

List Of Tables (50 Tables)

Table 1 Yearly Cost of Drugs in North America & Japan, 2013 ($)
Table 2 Yearly Cost of Drugs in European Countries, 2013 ($)
Table 3 Dosage Pattern of All Drugs
Table 4 Acute Lymphocytic Leukemia Drugs: Patent Status
Table 5 Acute Lymphocytic Leukemia Drugs: Market Revenue, By Type, 2011-2020 ($Million)
Table 6 Acute Lymphocytic Leukemia Drugs/Regimens Market Revenue, 2011-2020 ($Million)
Table 7 Acute Lymphocytic Leukemia Regimen (Hyper-Cvad) Market Revenue, By Country, 2011-2020 ($Million)
Table 8 Acute Lymphocytic Leukemia Regimen (Calgb 8811) Market Revenue, By Country, 2011-2020 ($Million)
Table 9 Acute Lymphocyitc Leukemia Drugs (Linker Regimen) Market Revenue, By Country, 2011-2020 ($Million)
Table 10 Acute Lymphocytic Leukemia Drug Class (Nucleoside Metabolic Inhibitors) Market Revenue, By Country, 2011-2020($Million)
Table 11 Acute Lymphocytic Leukemia Drugs (Oncaspar) Market Revenue, By Country, 2011-2020 ($Million)
Table 12 Product Pipeline Molecules: Phase Iii For Acute Lymphocytic Leukemia
Table 13 Acute Lymphocytic Leukemia Drugs-Pipeline (Graspa): Market Revenue, By Country, 2015-2020 ($Million)
Table 14 Acute Lymphocytic Leukemia Drugs-Pipeline (Marqibo): Market Revenue, By Country, 2013-2020 ($Million)
Table 15 Acute Lymphocytic Leukemia Drugs-Pipeline (Inotuzumab Ozogamicin): Market Revenue, By Country, 2015-2020 ($Million)
Table 16 Acute Lymphocytic Leukemia Therapeutics Market in G8 Countries, By Geography, 2011-2020 ($Million)
Table 17 U.S.: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 18 U.S.: Existing Regimens/Drugs Market Revenue, 2011-2020 ($Million)
Table 19 U.S.: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 20 Canada: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 21 Canada: Existing Regimens/Drugs Market Revenue, 2011-2020 ($Million)
Table 22 Canada: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 23 U.K.: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 24 U.K.: Existing Regimens/Drugs Market Revenue, 2011-2020 ($Million)
Table 25 U.K.: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 26 Germany: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 27 Germany: Existing Regimens/ Drugs Market Revenue, 2011-2020 ($Million)
Table 28 Germany: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 29 France: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 30 France: Existing Regimen/ Drugs Market Revenue, 2011-2020 ($Million)
Table 31 France: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 32 Italy: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 33 Italy: Existing Regimens/Drugs Market Revenue, 2011-2020 ($Million)
Table 34 Italy: Pipeline Drugs Market Revenue, 2011-2020 ($Million)
Table 35 Italy: Pipeline Drugs Market Share, 2015 Vs. 2020
Table 36 Spain: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 37 Spain: Existing Regimens/ Drugs Market Revenue, 2011-2020 ($Million)
Table 38 Spain: Pipeline Drugs Market Revenue, 2012-2020 ($Million)
Table 39 Japan: Acute Lymphocytic Leukemia Epidemiology, 2011-2020
Table 40 Japan: Existing Regimens/ Drugs Market Revenue, 2011-2020 ($Million)
Table 41 Japan: Pipeline Drugs Market Revenue, 2011-2020 ($Million)
Table 42 Erytech Pharma: Product Pipeline
Table 43 Erytech: Total Operating Revenue and R&D Expenditure, 2010-2012 ($Million)
Table 44 Genzyme Corporation: Product Portfolio
Table 45 Genzyme Corporation: Total Revenue and R&D Expenditure, 2008-2010 ($Million)
Table 46 Talon Therapeutics, inc.: Pipeline Product Portfolio
Table 47 Talon Therapeutics, inc.: Total R&D Expenditure, 2008-2012 ($Million)
Table 48 Sigma-Tau Group: Total Revenue, 2008-2012 ($Million)
Table 49 Pfizer, inc.: Total Revenue and R&D Expenditure, 2008-2012 ($Million)
Table 50 Galxosmithkline PLC: Total Revenue & R&D Expenses, 2008-2012 ($Million)


List Of Figures (28 Figures)

Figure 1 Acute Lymphocytic Leukemia Therapeutics Market in G8 Countries, By Existing Regimens/Drugs ($Million)
Figure 2 Market in G8 Countries, By Product Pipeline ($Million)
Figure 3 Status of Acute Lymphoblastic Leukemia Therapeutics Product Pipeline
Figure 4 Acute Lymphoblastic Leukemia Therapeutics Market, By Country
Figure 5 Most Common Types of Leukemia
Figure 6 Total Leukemia Population, By Country, 2008-2020
Figure 7 Acute Lymphocytic Leukemia: Age At Diagnosis
Figure 8 Stages and Phases of Acute Lymphocytic Leukemia
Figure 9 Acute Lymphocytic Leukemia: Population, By Country, 2008-2020
Figure 10 Market Revenue, By Top 10 Therapeutic Class ($Billion)
Figure 11 Erytech and Talon: Product Pipeline
Figure 12 Acute Lymphoblastic Leukemia Existing Regimens/Drugs Market Share, By Types, 2013 Vs 2015 Vs 2020
Figure 13 Acute Lymphocytic Leukemia Pipeline Regimens/Drugs Market Share, By Types, 2015 Vs 2020
Figure 14 U.S.: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020 ($Million)
Figure 15 U.S: Acute Lymphoblastic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 16 Canada: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 17 Canada: Acute Lymphoblastic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 18 U.K.: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 19 U.K.: Acute Lymphoblastic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 20 Germany: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 21 Germany: Acute Lymphoblastic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 22 France: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 23 France: Acute Lymphoblastic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 24 Italy: Acute Lymphocytic Leukemia Therapeutics-Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 25 Spain: Acute Lymphoblastic Leukemia Therapeutics-Existing Regimens/ Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 26 Spain: Acute Lymphocytic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020
Figure 27 Japan: Acute Lymphoblastic Leukemia Therapeutics-Existing Regimens/Drugs Market Share, 2013 Vs. 2015 Vs. 2020
Figure 28 Japan: Acute Lymphocytic Leukemia Therapeutics-Pipeline Drugs Market Share, 2015 Vs. 2020

★調査レポート[世界の急性リンパ性白血病/急性リンパ芽球性白血病治療市場] ( Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market-(Pipeline Forecast & Market Forecast in G8 Countries) (2011-2020) / MAM40116001) 販売に関する免責事項
[世界の急性リンパ性白血病/急性リンパ芽球性白血病治療市場] ( Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market-(Pipeline Forecast & Market Forecast in G8 Countries) (2011-2020) / MAM40116001) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆